News
21.05.2020

REGISTER NOW! Webinar: Your Trial Post-COVID: Recovery Must Start Now, Friday, 29 May 2020

Cromos Pharma, in association with MKR Clinical Research Consultants, presents a webinar: 

Your Trial Post-COVID: Recovery Must Start Now 

Friday, 29 May 2020

(9am PST, 12pm EST, 6pm CET)

REGISTER NOW

Join our experts for a forward-looking webinar focused on getting your clinical trials back on track as many countries begin to lift COVID-19 pandemic restrictions. By using scenario-based modelling our team has developed a comprehensive roadmap for restarting clinical trials as we move into a new phase of dealing with the pandemic.

Webinar Overview

The COVID-19 pandemic has had a significant impact on the clinical trial industry with many trials halted, others postponed while for those ongoing there has been a shift to remote and virtual communications with trial sites. There is growing recognition that we will be dealing with this pandemic for some time and that its effects will be far reaching, changing the ways in which clinical research has been traditionally conducted. In the light of this, it is imperative that we consider what actions are needed to resume clinical trials amid these new conditions. 

Cromos Pharma has approached this challenging task by taking an ongoing international trial and subjecting it to extensive risk assessment and scenario-based modeling. The trial metrics were analysed based on different actions, from waiting for the return of business as usual to the most aggressive rescue measures available. 

After studying the outcomes our expert team has come up with a comprehensive roadmap to navigate the “new normal” and get clinical trials up and running in the most effective and efficient manner possible.

Join us to see the range of actions required to ensure preparedness for restarting clinical trials as the pandemic enters a more controlled phase. Register now!

 Speakers 

Vlad.png 

 

Vlad Bogin, MD, FACP 

CEO & Founder @Cromos Pharma

Dr. Bogin started his medical training at Moscow Medical Academy, then trained at Yale and Brown Universities and received his postgraduate training at the University of Rochester where he was also elected to a chief medical resident position. Dr. Bogin has been involved in the drug development cycle for over 15 years, from basic discovery research to clinical trial design and execution. As a director at Boehringer Ingelheim he was in charge of late stage development of a leading cardiology product. As the Chairman of the Board at Medistem Inc., Dr. Bogin was instrumental in advancing the company from the preclinical to clinical stage, from a non-reporting to a fully reporting publicly trading company, and for a subsequent successful liquidity event in early 2014. Dr. Bogin maintains active medical license and hospital privileges and is an advisor to numerous companies and non-profit organizations. Dr. Bogin is an author of numerous peer-reviewed articles, book chapters and patents. 

Steph.png   

Stephanie Finnegan, MBA 

COO @Cromos Pharma 

Stephanie Finnegan is the Chief Operating Officer of Cromos Pharma, and is responsible for global operations, spanning North America, Europe, and Asia. She has thirty years of experience in pharmaceutical drug development, ranging from M&A and portfolio management to biomanufacturing and clinical research. She founded the biotech industry’s first contract manufacturer specializing strictly in recombinant proteins and monoclonal antibodies. For the past fifteen years, she has been working as a leader in CRO organizations, using her broad experience to specialize in biologics, biosimilars, and oncology/immunology. Stephanie has a BS in mathematics and an MBA/CPA.

Photo.png 

Jason Rubine, MSH 

Director of Clinical Operations @MKR Clinical Research Consultants

Jason Rubine is a clinical research professional with 15+ years of industry experience at the Sponsor and CRO levels across numerous therapeutic areas. With his combined scientific and research knowledge, he understands the most intricate details of the research industry in order to bring the clinical trials to success. Mr. Rubine heads up a geographically dispersed team and contributes heavily toward MKRs operational excellence. In addition, Mr. Rubine provides a lead role in client management, working with client managers and vendors within the industry to meet their needs for staffing solutions. Jason has a bachelor’s degree in Nutritional Science from The Pennsylvania State University and a master’s degree in Nutritional Science from The University of North Florida.  

Vladimir.png   

Vladimir Krechikov, MD, PhD 

Head of Region, Eastern Europe @Cromos Pharma

Dr Vladimir Krechikov started his career in clinical research as an investigator, then worked at various positions in clinical operations of global CROs before transitioning to a Director of Business Development position at one of the largest regional CROs. More than 10 years ago, Dr. Krechikov moved to Cromos Pharma, where he held various positions in Business Development and is now Head of Region, Eastern Europe. He graduated from Smolensk State Medical Academy (Russia) as a medical doctor, then received his postgraduate training at Queen Mary University of London (UK) and received PhD in clinical pharmacology. He is an author of more than 30 scientific publications in peer-reviewed journals.

Zsolt.png   

Zsolt Kocsis, MD, MBA

Country Head, Hungary @Cromos Pharma

Zsolt Kocsis is a clinical research professional with 12+ years of industry experience at sponsor and CRO levels across numerous therapeutic areas. Dr. Kocsis heads the Hungarian Office of Cromos Pharma and contributes to Cromos Pharma’s Central European operations. Zsolt holds a medical degree (MD) and a business degree (MBA). 

 

 

 

Other News:
news

Watch our video: Navigating an era of uncertainty

We are pleased to share with you our new video Cromos Pharma: Helping to navigate an era of uncertainty.

02.09.2020
news

Webinar: Where in the world should I locate my pivotal clinical trial?

01.09.2020
news

EU cancer estimates for 2020 reveal 2.7 million new cases

The European Joint Research Council released its 2020 burden of cancer estimates on 22 July, 2020. The report revealed The cancer burden is estimated to have risen to 2.7 million new cases (all types, excluding non-melanoma skin cancer) and 1.3 million deaths in 2020. Female breast cancer remains the most commonly diagnosed.
26.07.2020
news

FDA proposes new rule on reporting requirements to support Right to Try

On July 23, the U.S. Food and Drug Administration (FDA) announced a new proposed rule that would require sponsors and manufacturers who provide an ‘‘eligible investigational drug’’ under the Right to Try Act to submit an annual summary of such use to FDA.
26.07.2020
news

European medicines agencies launch public consultation on joint strategy

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have developed a joint strategy for the next five years. It was released for a two-month public consultation period on 6, July, 2020.
14.07.2020
news

Two new reports find impacts of COVID-19 on clinical trials easing slightly

Two new reports released by GlobalData Healthcare and Medidata find evidence of COVID-19 impacts on clinical trials easing slightly. 
13.07.2020
news

Risk Based Monitoring- a data-centric approach to monitoring

In this Insights@CromosPharma article our Chief Operating Officer Stephanie Finnegan explores the role of Risk Based Monitoring (RBM) in clinical trials, how it has been utilized in response to the current coronavirus pandemic, and how the experience may shape the industry's approach to RBM in the future.
30.06.2020
news

Cromos Pharma Recruits over 300 Patients in Under Two Months into a COVID-19 Clinical Trial

Cromos Pharma, an international CRO, is pleased to announce unprecedented recruitment in a phase IIb trial in patients with moderate to severe COVID-19 infection.
18.06.2020
news

Connect with Cromos Pharma at BIO Digital 2020

Cromos Pharma is delighted to be participating in BIO Digital 2020, June 8-12 2020. 
02.06.2020
news

Cromos Pharma celebrates International Clinical Trials Day 2020

Today (20 May, 2020) marks International Clinical Trials Day 2020. Cromos Pharma wishes to express its gratitude to everyone who participates in  and conducts clinical trials that help turn research into reality and make lifesaving and life-changing medical treatments available to patients all over the world.
20.05.2020
news

First patients enrolled in Cromos Pharma managed Covid-19 trial

Cromos Pharma is proud to be part of the global search for effective COVID-19 treatments. Today (24 April, 2020) we are pleased to announce the enrollment of the first patients in clinical trials designed to be find drugs to treat the symptoms of coronavirus.
27.04.2020
news

Cromos Pharma insights on master protocols

Master protocols are disrupting the clinical trial space by offering a more comprehensive and adaptive approach to studying treatments for the most complex of diseases. Cromos Pharma is delighted to share with you a recently published article on the topic by CEO Dr Vlad Bogin.
27.04.2020
news

Cromos Pharma supporting World Immunization Week

Vaccines are some of our most powerful weapons against deadly diseases. Cromos Pharma salutes all those involved in the development, administration and promotion of vaccines all over the world.
23.04.2020
news

Cromos Pharma wishes you a safe and healthy Easter and Passover

At the most difficult time, the entire Cromos Pharma Team wishes all our patients, clients, investigators, site personnel and partners a safe and healthy Easter and Passover.
10.04.2020
news

European Medicines Agency launches new regulatory science strategy

The European Medicines Agency (EMA) recently (31 March 2020) published its Regulatory Science Strategy to 2025. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines.
08.04.2020
news

Cromos Pharma to run COVID-19 trial

Cromos Pharma is pleased to announce that it has been enlisted to run a clinical trial of a repurposed drug candidate to treat COVID-19.  
01.04.2020
news

Cromos Pharma committed to delivering in the face of COVID-19 challenges

Cromos Pharma has been closely following the COVID-19 outbreak as it continues to spread across the globe.
13.03.2020
news

Cromos Pharma launches new series to explore the latest developments in clinical trials sector

2020 marks the start of a new decade when we can anticipate several trends to take hold in the global clinical research market. What can we expect in terms of the market in terms of growth and trends? Throughout 2020 Cromos Pharma’s team of experts will look at some of the major trends dominating the current market and future influences on clinical research.
09.03.2020
news

Celebrating the Women of Cromos Pharma on IWD 2020

On the occasion of International Women’s Day (8 March 2020) we at Cromos Pharma are celebrating the enormous contribution of our female team members.
08.03.2020
news

Cromos Pharma launches a new office in Warsaw, Poland

Cromos Pharma, an international provider of clinical trial and drug development services, today (04 MARCH 2020) announced the opening of its new office in Warsaw, Poland. The opening of the new office strengthens Cromos Pharma’s position in Poland where it has been operational since 2015.

“The establishment of the Poland office is a major development in line with Cromos Pharma’s continued expansion in European and US operations marking another milestone in the sustained growth of the Company. Poland is a significant clinical trials market that has many advantages making it highly attractive to international sponsors,” said Dr. Vlad Bogin, CEO, Cromos Pharma, “Cromos Pharma looks forward to offering sponsors an extended range of our expert services through its new office to ensure effective and cost-efficient execution of clinical trials”.

With its 40 million people Poland is one of the largest clinical trials markets in Eastern Europe that has a strong track record of over 20 years in delivering high-quality research. It boasts several advantages including a large naïve population and well-developed research infrastructure. Polish patients are positively disposed to taking part in clinical trials as it offers them an opportunity to access innovative treatments otherwise not always available to them. The country has a large network of highly skilled and motivated clinical investigators and medical professionals keen to participate in clinical research. Poland also offers relatively low costs and excellent patient recruitment.

With excellent rates of patient recruitment, high-quality data, highly skilled and committed investigators, and comparatively low costs, Poland is an attractive location for sponsors. Cromos Pharma is ready to help you access these advantages through our excellent knowledge of the regulatory processes and our existing relationships with sites and investigators.

Learn more about conducting clinical trials in Poland with Cromos Pharma here.

To explore these advantages and the services Cromos Pharma can offer you please email bd@cromospharma.com.

About Cromos Pharma

Cromos Pharma is an international Contract Research Organization (CRO) providing tailored and effective clinical trials management to support the development of drugs that transform healthcare. It offers fully integrated services with expertise in all aspects of clinical trials of all phases in a wide range of therapeutic indications. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has an extensive network of offices across 15 countries and strong regional experience in Central and Eastern Europe. Its European HQ is situated in Dublin, Ireland and its US base is in Portland, Oregon with an operational base in South Florida.
04.03.2020
news

Cromos Pharma attends Asia Matters briefing

21.01.2020
news

Thank you for your business and support throughout 2019. We look forward to working with you in 2020!

On behalf of everyone at Cromos Pharma I would like to wish our clients and partners a very happy and healthy holiday season. Thank you for your business and support throughout 2019. We look forward to working with you in 2020!
17.12.2019
news

Meet Cromos Pharma’s CEO at the 38th Annual J.P Morgan Healthcare Conference

09.12.2019
news

Meet Cromos Pharma at 61st ASH Annual Meeting & Exposition

29.11.2019
news

Thanksgiving Message

27.11.2019
news

Our medical writing team is focused on delivering the results you need.

31.10.2019
news

Cromos Pharma celebrating 15 years of excellence in clinical research

24.10.2019
news

Join us at ESMO in Barcelona on September 27 - October 1, 2019

19.09.2019
news

Meet us at Outsourcing in Clinical Trials Pacific Northwest in Seattle on October 16 - 17 2019

19.09.2019
news

Meet the Cromos Pharma team at the 2019 KoNECT-MOHW-MFDS International Conference to be held on September 17 – 19 in Seoul, South Korea.

30.08.2019
news

Cromos Pharma CEO highlights opportunities and challenges for small sponsors at MAGI Clinical Research Conference

20.08.2019
news

Cromos Pharma sets a new record in site initiation timelines in Poland

15.08.2019
news

Cromos Pharma's "Your Perfect CRO" Survey shows surprising results

24.07.2019
news

Cromos Pharma recruits 473 patients (92% of total) into a breast cancer trial, all in under 7 months.

17.06.2019